Gaudig, M., Richarz, U., Han, J., Van Baelen, B., Schäuble, B.

To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies (Studies 1 and 2) were performed. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials (parent trials) involving patients with mild to moderate Alzheimer’s disease (AD). In Study 1 (GAL-USA-11; n’723), […]

Freund, Hans-Joachim, Kuhn, Jens, Lenartz, Doris, Mai, Jürgen K., Schnell, Thomas, Klosterkoetter, Joachim, Sturm, Volker

Background: Dementia represents one of the most challenging health problems. Despite intense research, available therapies have thus far only achieved modest results. Deep brain stimulation (DBS) is an effective treatment option for some movement disorders and is under study for psychiatric applications. Recently, diencephalic DBS revealed selective effects on memory functions, another facet of subcortical […]

Emre, Murat, Poewe, Werner, De Deyn, Peter Paul, Barone, Paolo, Kulisevsky, Jaime, Pourcher, Emmanuelle, van Laar, Teus, Storch, Alexander, Micheli, Federico, Burn, David, Durif, Frank, Pahwa, Rajesh, Callegari, Francesca, Tenenbaum, Nadia, Strohmaier, Christine

Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]

Dodel, Richard, Rominger, Axel, Bartenstein, Peter, Barkhof, Frederik, Blennow, Kaj, Förster, Stefan, Winter, Yaroslav, Bach, Jan-Philipp, Popp, Julius, Alferink, Judith, Wiltfang, Jens, Buerger, Katharina, Otto, Markus, Antuono, Piero, Jacoby, Michael, Richter, Ralph, Stevens, James, Melamed, Isaac, Goldstein, Jerome, Haag, Stefan, Wietek, Stefan, Farlow, Martin, Jessen, Frank

Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]

Buerger, Katharina, Frisoni, Giovanni, Uspenskaya, Olga, Ewers, Michael, Zetterberg, Henrik, Geroldi, Cristina, Binetti, Giuliano, Johannsen, Peter, Rossini, Paolo Maria, Wahlund, Lars-Olof, Vellas, Bruno, Blennow, Kaj, Hampel, Harald

Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]

Bartholomeyczik, S., Reuther, S., Luft, L., Nie, N. van, Meijers, J., Schols, J., Halfens, R.

Aim Of the Study: The aims of this study were to test the transfer and feasibility of a Dutch annual survey on malnutrition into German nursing homes and to gather first data about the prevalence of malnutrition, treatment and quality indicators in German resident homes.; Methods: A cross-sectional multicentre study, using a standardised multilevel instrument […]

Allgaier, Antje-Kathrin, Kramer, Dietmar, Mergl, Roland, Fejtkova, Sabina, Hegerl, Ulrich

Objective: To assess and compare the validity of the German 15-item version and shortened versions of the Geriatric Depression Scale (GDS) for early detection of depression in nursing home residents with mild to moderate cognitive impairment (MMSE ≥ 15).; Methods: Data from 92 patients were analysed. The Structural Clinical Interview for DSM-IV (SCID) was used as […]